FDA puts its foot down on Makena: New meta-analysis does not change call to pull the drug

A recently published meta-analysis of 31 randomized, controlled trials on the premature birth drug Makena is not changing the FDA’s previous decision to pull its accelerated approval and remove it from the market, the agency said late last week.